Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson’s Disease

BACKGROUND: Intraputamenal glial cell line-derived neurotrophic factor (GDNF), administered every 4 weeks to patients with moderately advanced Parkinson’s disease, did not show significant clinical improvements against placebo at 40 weeks, although it significantly increased [(18)F]DOPA uptake throu...

詳細記述

保存先:
書誌詳細
出版年:J Parkinsons Dis
主要な著者: Whone, Alan L., Boca, Mihaela, Luz, Matthias, Woolley, Max, Mooney, Lucy, Dharia, Sonali, Broadfoot, Jack, Cronin, David, Schroers, Christian, Barua, Neil U., Longpre, Lara, Barclay, C. Lynn, Boiko, Chris, Johnson, Greg A., Fibiger, H. Christian, Harrison, Rob, Lewis, Owen, Pritchard, Gemma, Howell, Mike, Irving, Charlie, Johnson, David, Kinch, Suk, Marshall, Christopher, Lawrence, Andrew D., Blinder, Stephan, Sossi, Vesna, Stoessl, A. Jon, Skinner, Paul, Mohr, Erich, Gill, Steven S.
フォーマット: Artigo
言語:Inglês
出版事項: IOS Press 2019
主題:
Research Report
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6597995/
https://ncbi.nlm.nih.gov/pubmed/30829619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/JPD-191576
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料